Filing Details
- Accession Number:
- 0001415889-25-007856
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2025-03-12 17:20:05
- Reporting Period:
- 2025-03-10
- Filing Date:
- 2025-03-12
- Accepted Time:
- 2025-03-12 17:20:05
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1070081 | Ptc Therapeutics Inc. | PTCT | Pharmaceutical Preparations (2834) | 043416587 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1578852 | Elliott Mark Boulding | C/O Ptc Therapeutics, Inc. 500 Warren Corporate Center Drive Warren NJ 07059 | Exec. Vp And Clo | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2025-03-10 | 45,392 | $33.02 | 149,293 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2025-03-10 | 45,392 | $53.15 | 103,901 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2025-03-10 | 11,398 | $33.02 | 115,299 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2025-03-10 | 11,398 | $53.12 | 103,901 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2025-03-10 | 11,249 | $25.69 | 115,150 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2025-03-10 | 3,487 | $52.24 | 111,663 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2025-03-10 | 7,762 | $53.05 | 103,901 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2025-03-11 | 5,662 | $33.02 | 109,563 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2025-03-11 | 5,662 | $53.02 | 103,901 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2025-03-11 | 1,719 | $33.02 | 105,620 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2025-03-11 | 1,719 | $53.01 | 103,901 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2025-03-10 | 45,392 | $0.00 | 45,392 | $33.02 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2025-03-10 | 11,398 | $0.00 | 11,398 | $33.02 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2025-03-10 | 11,249 | $0.00 | 11,249 | $25.69 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2025-03-11 | 5,662 | $0.00 | 5,662 | $33.02 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2025-03-11 | 1,719 | $0.00 | 1,719 | $33.02 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 18,788 | 2029-01-21 | No | 4 | M | Direct | |
| 4,114 | 2029-01-21 | No | 4 | M | Direct | |
| 33,751 | 2034-02-14 | No | 4 | M | Direct | |
| 13,126 | 2029-01-21 | No | 4 | M | Direct | |
| 2,395 | 2029-01-21 | No | 4 | M | Direct |
Footnotes
- This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on December 5, 2024.
- This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $53.00 to $53.82 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $53.00 to $53.57 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $51.73 to $52.71 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $52.74 to $53.57 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $53.00 to $53.14 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $37.30 to $38.20 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- Currently exercisable.
- This option was granted on February 15, 2024, and vests over four years, with 25% of the shares underlying the option vesting on February 15, 2025, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on May 15, 2025.
Billionaire Hedge Funds
